Brought to you by 
Immusol designs ribozymes for Pfizer targets
13 Jul 1999
Executive Summary
Immusol has agreed to work with Pfizer indefinitely to validate new therapeutic targets in Pfizer's pipeline. Pfizer will first provide Immusol with gene target sequences so that it can design specific ribozymes to each target.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Immusol designs ribozymes for Pfizer targets
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice